projects:workgroups:clinicalstudy
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
projects:workgroups:clinicalstudy [2024/04/28 20:17] zhen |
projects:workgroups:clinicalstudy [2025/05/11 15:58] (current) mikehamidi |
||
|---|---|---|---|
| Line 10: | Line 10: | ||
| **Status**:\\ | **Status**:\\ | ||
| - | - 2022: CTWG was given access to 20 Vivli clinical study packages in the SDTM format. The CTWG team is doing an inventory of those study packages in order to prioritize SDTM-to-OMOP mappings. The existing CTWG guidance topics will be further assessed and new ones identified where necessary. \\ | + | - 2025: CTWG is providing new chapter content (Clinical Trial Data) for the upcoming Book of OHDSI update. |
| - | - 2021: CTWG did an assessment of clinical trial data providers where SDTM data could be accessed. This eventually led to discussions with Vivli (i.e., general data usage agreements and platform feasibility evaluation). \\ | + | - 2024: The finalization of C-Path SDTM-to-OMOP mappings is underway, with an emphasis on matching concept codes using Usagi. The next step is to execute ETL queries to generate the OMOP CDM tables. Additionally, a secondary objective is to identify general conventions and best practices for clinical trials. These conventions will be applied to additional C-Path SDTM study data to uncover any further gaps or challenges. \\ |
| + | - 2023: The team has transitioned from using Vivli (due to access constraints) data to leveraging SDTM data provided by C-Path for tuberculosis. The development of mapping specifications for the subsequent ETL process will proceed from the initial stages.\\ | ||
| + | - 2022: CTWG has been granted access to 20 Vivli clinical study packages in SDTM format. The team is conducting an inventory of these study packages to prioritize SDTM-to-OMOP mappings. The current CTWG guidance topics will be further evaluated, with new topics identified as needed. \\ | ||
| + | - 2021: CTWG conducted an assessment of clinical trial data providers to identify sources of accessible SDTM data. This assessment led to discussions with Vivli, focusing on general data usage agreements and evaluating the feasibility of their platform. \\ | ||
| - 2020: Used a synthetic representation of the CDISC SDTM data via PHUSE Test Data. Initial guidance topics were codified but require further testing with diverse real world SDTM data. The CTWG proposals submitted to the OHDSI community in July 2020.\\ | - 2020: Used a synthetic representation of the CDISC SDTM data via PHUSE Test Data. Initial guidance topics were codified but require further testing with diverse real world SDTM data. The CTWG proposals submitted to the OHDSI community in July 2020.\\ | ||
| </WRAP> | </WRAP> | ||
| Line 25: | Line 28: | ||
| https://github.com/OHDSI/ClinicalTrialsWGETL | https://github.com/OHDSI/ClinicalTrialsWGETL | ||
| - | Recent WG Updates: [[https://youtu.be/pWW72a9A5YE|Nov. 2022 Presentation]]; [[https://youtu.be/ctPADsAoYpM|Oct. 2021 Presentation]] and [[https://ohdsiorg.sharepoint.com/:b:/s/Workgroup-Clinicaltrials/EXbVRrl7hQNEiPhC48Zx0t4BfILfVjMiW85MtWBmGHRzFA?e=nThgMV|Slides]] | + | Recent WG Updates: |
| + | [[https://www.ohdsi-europe.org/images/symposium-2024/Posters/CTWG%20OHDSI%20Europe%20poster_v3%20-%20Cynthia%20Sung.pdf|2024 EU OHDSI Symposium Poster]]; [[https://youtu.be/pWW72a9A5YE|Nov. 2022 Presentation]]; [[https://youtu.be/ctPADsAoYpM|Oct. 2021 Presentation]] and [[https://ohdsiorg.sharepoint.com/:b:/s/Workgroup-Clinicaltrials/EXbVRrl7hQNEiPhC48Zx0t4BfILfVjMiW85MtWBmGHRzFA?e=nThgMV|Slides]] | ||
| ---- | ---- | ||
| ==== Meetings ==== | ==== Meetings ==== | ||
| - | {{:projects:workgroups:ct_wg_ohdsi2021fallsymp.png?direct&300|}} | ||
| - | **Bi-weekly Friday WG Meeting Schedule** is accessible on OHDSI Teams environment. \\ | + | **Bi-weekly on Fridays from 11:30 AM to 12:00 PM EST (Eastern Standard Time) or 4:30 PM to 5:00 PM UTC (Universal Time Coordinated)** is accessible on the OHDSI Teams environment. \\ |
| *** Note on accessing Teams channel:**\\ | *** Note on accessing Teams channel:**\\ | ||
| Line 42: | Line 45: | ||
| **WG co-leads**: | **WG co-leads**: | ||
| - | Mike Hamidi, | + | Open Spot |
| and | and | ||
| - | TBD | + | Kenneth Wilkins |
| + | **WG past leads**: | ||
| + | Mike Hamidi, Tom Walpole, Zhen Li, Sonia Araujo | ||
| **Active members**\\ | **Active members**\\ | ||
| Line 55: | Line 60: | ||
| | Melissa Cook | Essex Management | Boston, MA, USA | [[http://www.linkedin.com/in/mkcook|{{:wiki:linkedinicon.png?20}}]] | | | Melissa Cook | Essex Management | Boston, MA, USA | [[http://www.linkedin.com/in/mkcook|{{:wiki:linkedinicon.png?20}}]] | | ||
| | Diane Corey | Critical Path Institute | Tucson, AZ, USA | | | | Diane Corey | Critical Path Institute | Tucson, AZ, USA | | | ||
| - | | Shital Desai | | USA | | | + | | Shital Desai | Independent | USA | | |
| - | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | Bethesda, MD, USA | [[https://www.linkedin.com/in/kerrygoetz/|{{:wiki:linkedinicon.png?20}}]] | | + | | Kerry Goetz | National Institute of Health; \\ National Eye Institute | Bethesda, MD, USA | [[https://www.linkedin.com/in/kerrygoetz/|{{:wiki:linkedinicon.png?20}}]] |
| - | | Priya Gopal | Flatiron Health | New York, NY, USA | | | + | | Mike Hamidi | Walmart Healthcare Research Institute | USA | [[https://www.linkedin.com/in/kamiar-mike-hamidi-0a908164/|{{:wiki:linkedinicon.png?20}}]] | |
| - | | Mike Hamidi | | USA | [[https://www.linkedin.com/in/kamiar-mike-hamidi-0a908164/|{{:wiki:linkedinicon.png?20}}]] | | + | | Dan Hartley | Critical Path Institute | USA | | |
| - | | Dan Hartley | | USA | | | + | |
| | Ying Huang |National Institute of Health | USA | | | | Ying Huang |National Institute of Health | USA | | | ||
| | Asiyah Yu Lin | National Institute of Health | Bethesda, MD, USA | | | Asiyah Yu Lin | National Institute of Health | Bethesda, MD, USA | | ||
| Line 66: | Line 70: | ||
| | Terrence McHugh | Critical Path Institute | Tucson, AZ, USA | | | | Terrence McHugh | Critical Path Institute | Tucson, AZ, USA | | | ||
| | Priya Meghrajani | Talosix | Seattle, WA, USA | | | | Priya Meghrajani | Talosix | Seattle, WA, USA | | | ||
| - | | Pam Nesbitt | | USA | | | ||
| | Paul Orona | | USA | | | | Paul Orona | | USA | | | ||
| | Daniel Olson | Critical Path Institute | Tucson, AZ, USA | | | | Daniel Olson | Critical Path Institute | Tucson, AZ, USA | | | ||
projects/workgroups/clinicalstudy.1714335431.txt.gz · Last modified: 2024/04/28 20:17 by zhen
Page Tools
